

# HEALTH TECH ALLIANCE

## MedTech Funding Mandate

### Background

The NHS Long Term Plan committed to the development of the MedTech Funding Mandate, later consulting on the policy in December 2019. The Mandate's launch was delayed from April 2020 due to Covid-19.

### MedTech Funding Mandate Policy

The policy is effective from 1 April 2021 and the Accelerated Access Collaborative (AAC) is responsible for identifying innovations for the policy, supported by input from various stakeholders.

### 2021/22 Mandate

The 2021/22 Mandate will apply to devices, diagnostics, and digital products that:

- Are effective as demonstrated through a positive NICE MTG or DG.
- Deliver material savings to the NHS – over £1m over five years for the population of England.
- Are cost-saving in-year – deliver a net saving in the first 12 months of being implemented (this was retained in light of the ongoing pressures the NHS faces)
- Are affordable to the NHS – the budget impact should not exceed £20m in any of the first three years.

A fifth criterion, that products previously supported through the ITT/ITP programmes will be eligible, is in place only for the 2021/22 Mandate.

The technologies that meet the five criteria are:

- **placental growth factor based testing (PIGF)** – a diagnostic test to help rule out pre-eclampsia (Triage PIGF test and the Elecsys immunoassay sFlt-1/PIGF ratio)
- **SecurAcath** – for securing percutaneous catheters
- **HeartFlow FFRCT** – for estimating fractional flow reserve from coronary CT angiography
- **gammaCore** – a handheld device which alleviates the symptoms of severe cluster headaches by stimulating the vagus nerve

### Criteria for the MedTech Funding Mandate from 1 April 2022

- From 1 April 2022, technologies not previously supported by the ITT/ITP may be covered by the Mandate.
- **Technologies will need to demonstrate a net saving across a three-year period (rather than in-year savings).**
- Technologies that have their MTG or DG published up to and including the 30 June 2021 will be reviewed to identify products that:
  - Are effective as demonstrated through a positive NICE MTG or DG.
  - Are cost-saving within three years.
  - Are affordable to the NHS – the budget impact should not exceed £20m in any of the first three years.